Chi-Med covers $100m Nasdaq IPO as leads target US
Hutchison China MediTech’s (Chi-Med) $100m IPO on the Nasdaq was oversubscribed three days into bookbuilding, even as bankers pinned their hopes on a select group of US funds.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts